Posted On: 12/19/2014 3:06:31 AM
Post# of 30034
Re: Ea$y Money #13402
Actually ESS acquisition could be the biggest one for AMBS given its history with IND already filed with ODD status and no competition. It will come down to execution of phase II.
For AMBS fundamentals are solid in case of Lympro and ESS. It is just matter of time before Lympro can be commercialized.
ACAD is good example of what blockbuster drug can do to stock price. It is trading at $32 with no revenues and Primavanserin is in phase III and it will take at least couple of years to get approved by FDA. The company has already suffered significant loss (hundreds of millions) upto this point in phase II and III trial execution and few hundred million more in upcoming years but thanks to Allergan and funding from stock sales. The stock price is going up nonetheless.
It is all about science and execution and management has done great job executing phase II and rest is history.
For AMBS fundamentals are solid in case of Lympro and ESS. It is just matter of time before Lympro can be commercialized.
ACAD is good example of what blockbuster drug can do to stock price. It is trading at $32 with no revenues and Primavanserin is in phase III and it will take at least couple of years to get approved by FDA. The company has already suffered significant loss (hundreds of millions) upto this point in phase II and III trial execution and few hundred million more in upcoming years but thanks to Allergan and funding from stock sales. The stock price is going up nonetheless.
It is all about science and execution and management has done great job executing phase II and rest is history.
(0)
(0)Scroll down for more posts ▼
